Global Ebola virus infection drug market is rising with a substantial CAGR in the forecasted period of 2019-2026. This rise in market can be attributed to the increasing number of Ebola virus infected patients , growing prevalence of Ebola virus infections, the lack of a reliable cure for Ebola virus infections and steady government support to Ebola research, developing Ebola drugs and vaccines.
Get Exclusive Sample Copy of This Report Here https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-ebola-virus-infection-drug-market
The market dynamics study of this Ebola Virus Infection Drug Market business research report demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions different regions i.e. the geographical spread of the business. Under competitive market share evaluation, this document suggests that the key players dominate the operations in the industry attributable to their strong geographical reach & huge production facilities. The major players operating in the Ebola Virus Infection Drug Market are in strong competition in terms of technology, innovation, and pricing.
Few of the major competitors currently working in the global Ebola virus infection drug market are Merck & Co., Inc, NewLink Genetics Corporation, Johnson & Johnson Private Limited , GlaxoSmithKline plc, Novavax, GeoVax, Mapp Biopharmaceutical, Arbutus Biopharma, Bavarian Nordic , Nanoviricides, INC, Sarepta Therapeutics, Chimerix, Biocryst Pharmaceuticals, INC, Hemispherx Biopharma, Inc, BioComo Incorporation, Peptineo, Bio-Excel, Geneone Life Sciences, IMV Inc, Etubics.
Read Complete Details with TOC Here https://www.databridgemarketresearch.com/toc/?dbmr=global-ebola-virus-infection-drug-market
Market Definition: Global Ebola Virus Infection Drug Market
Ebola virus infection is a serious fatal condition which is caused by the four different species of Ebola virus in humans and non-human primates. It causes hemorrhagic fever which leads to internal and external bleeding and affects multiple organs. A person with Ebola virus infection at initial stage experiences sore throat, muscular pain, headaches. Vomiting, rashes and diarrhea at later stages along with decreased function of kidney and liver. At this stage some patients begin to bleed internally as well as externally. This infection has about average 50.0% of high risk of deaths.
According to WHO report dated 26 December 2018, a total of 591 Ebola virus infected cases, including 543 confirmed and 48 probable cases, have been reported from 16 health zones in the two neighboring provinces of North Kivu and Ituri. Of these cases, 54 were healthcare workers, of which 18 died. Overall, 357 cases have died (case fatality ratio 60.0%). In the past week, ten additional patients were discharged from Ebola treatment center overall, 203 patients have recovered to date. The highest number of cases was from age group 15‒49 years with 60.0% (355/589) of the cases, and of those, 228 were female. Peak attack rates have been detected in children aged more than one year (especially male infants) and females aged 15 years and older.
Segmentation: Global Ebola Virus Infection Drug Market
Ebola Virus Infection Drug Market : By Strain Type
- Tai forest
- Bundibugyo virus
Ebola Virus Infection Drug Market : Novel Drug Type
Ebola Virus Infection Drug Market : Vaccine Type
Ebola Virus Infection Drug Market : Route of Administration
Ebola Virus Infection Drug Market : By End Users
- Specialty Clinics
Ebola Virus Infection Drug Market : By Geography
- North America
- South America
- Middle East & Africa
Key Developments in the Ebola Virus Infection Drug Market:
- In March 2015, ChAd3-ZEBOV vaccine is developed by GlaxoSmithKline plc in collaboration with the US National Institute of Allergy and Infectious Diseases (NIAID) is under phase II/III of clinical trial and shows 90.0% efficacy rate, and the safety of vaccine and placebo is high.
- In April 2015, VSV-EBOV vaccine is developed by NewLink Genetics and Merck & Co., Inc. in collaboration with the Public Health Agency of Canada is under phase III of clinical trial and currently in use and shows very high efficacy rate and the vaccine regimen appears to be well tolerated by adult volunteers.
Ebola Virus Infection Drug Market Drivers
- Increasing number of Ebola virus infected patients
- Growing prevalence of Ebola virus infections around the world
- Increasing awareness about the infection
- Lack of a reliable cure for Ebola virus infections
- Steady government support for Ebola research including development of Ebola drugs and vaccines
Ebola Virus Infection Drug Market Restraints
- The unpredictable nature of Ebola has slow down research efforts
- Unavailability of effective treatment
- Lack of awareness among the patient and physician about chronic obstructive pulmonary disease treatment
Competitive Analysis: Global Ebola Virus Infection Drug Market
Global Ebola virus infection drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of ebola virus infection drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Want Full Report? Enquire Here https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-ebola-virus-infection-drug-market
About Data Bridge Market Research:
Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475 Mail: [email protected]